COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT
Completed
National University Hospital, Singapore
Phase 2/Phase 3
2007-08-01
This is a randomised controlled trial to investigate the efficacy of preventive regimen of
hydration with high dose oral N-acetylcysteine and intravenous sodium bicarbonate
pretreatment in patients with stable advanced renal insufficiency (CKD stage 3 and 4:GFR
15-60ml/min/1.73m2 calculated by Modification of Diet in Renal Disease Study equation (MDRD
formula)) undergoing elective percutaneous coronary intervention (PCI).
Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide
Completed
Seoul National University Bundang Hospital
Phase 4
2009-02-01
In the treatment of coronary heart disease which is the major cause of heart attack, direct
mechanical treatment with catheters such as the coronary angiography, coronary balloon
intervention and stenting intervention are the mainstay of therapy in recent years. In that
procedures, the investigators should use the contrast media, and it may cause kidney toxicity
especially in the patients with underlying kidney disease and decreased kidney function. The
investigators intended to find out which contrast agent has less kidney toxicity in the
catheter based treatment of coronary arterial diseases in patients with underlying decreased
kidney function
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
Completed
Ospedale della Misericordia - Grosseto
Phase 4
2008-12-01
The purpose of this study is to determine the incidence of contrast induced nephropathy and
myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide
administration in patients with acute myocardial infarction undergoing primary PCI.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.